Daraxonrasib raised 1-year survival from 18.7% to 53.3% in pancreatic cancer (NEJM)
Louis highlights the 500-person phase 3 trial of the oral RAS inhibitor daraxonrasib in patients who failed first-line therapy, published in NEJM alongside the ASCO presentation. It cut risk of death by 60% versus chemotherapy, a first for this setting.